Chen et al. designed second-generation mouse CAR-T cells targeting EGFRvIII with a CD28 co-stimulatory domain and extracellular scFv derived from antibody 806 (806-28Z-CAR-T cells) and tested their ability against mouse glioma cells in vitro and in vivo. Here, CD28 is linked to central nervous system cancer.